Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia

Genetic Predictors of AML Treatment Response

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01024127

Enrollment

2500

Registered

2009-12-02

Start date

2009-12-31

Completion date

Unknown

Last updated

2016-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission

Brief summary

This research trial studies deoxyribonucleic acid (DNA) in blood or bone marrow samples from younger patients with acute myeloid leukemia. Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.

Detailed description

PRIMARY OBJECTIVES: l. Perform a genome-wide scan to test for loci associated with acute myeloid leukemia (AML) relapse and infection risk. II. Validate positive associations seen in the genome-wide scan with a fine mapping approach. III. Perform simulated clinical trials using germline genetic variation data to test the feasibility of using genetic data to inform the clinical care of pediatric patients with AML. OUTLINE: Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.

Interventions

OTHERLaboratory Biomarker Analysis

Correlative studies

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

No minimum to 30 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of AML * In remission * Adequate DNA from peripheral blood or bone marrow samples * Concurrent enrollment on CCG-2961, COG-AAML03P1, COG-AAML0531, AML-93, AML-97, AML-04,AML-09, or Canada AML Infection clinical trial required

Design outcomes

Primary

Measure	Time frame
Incidence of first acute myeloid leukemia relapse	Up to 2 years
Rate of invasive bacterial infections defined as the number of invasive infection episodes divided by the days at risk	From study entry date to completion of therapy date provided on the final Reporting Period case reporting form, assessed up to 2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026